Translation of bi-directional transcripts enhances MHC-I peptide diversity

Antisense transcripts play an important role in generating regulatory non-coding RNAs but whether these transcripts are also translated to generate functional peptides remains poorly understood. In this study, RNA sequencing and six-frame database generation were combined with mass spectrometry anal...

Full description

Saved in:
Bibliographic Details
Main Authors: Filip Zavadil, Tomas Henek, Justine Habault, René Chemali, Maria Camila Tovar-Fernandez, Chrysoula Daskalogianni, Laurence Malbert-Colas, Lixiao Wang, Sivakumar Vadivel Gnanasundram, Borek Vojtesek, Lenka Hernychova, Sebastien Apcher, Robin Fahraeus
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1554561/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antisense transcripts play an important role in generating regulatory non-coding RNAs but whether these transcripts are also translated to generate functional peptides remains poorly understood. In this study, RNA sequencing and six-frame database generation were combined with mass spectrometry analysis of peptides isolated from polysomes to identify Nascent Pioneer Translation Products (Na-PTPs) originating from alternative reading frames of bi-directional transcripts. Two Na-PTP originating peptides derived from antisense strands stimulated CD8+ T cell proliferation when presented to peripheral blood mononuclear cells (PBMCs) from nine healthy donors. Importantly, an antigenic peptide derived from the reverse strand of two cDNA constructs was presented on MHC-I molecules and induced CD8+ T cell activation. The results demonstrate that three-frame translation of bi-directional transcripts generates antigenic peptide substrates for the immune system. This discovery holds significance for understanding the origin of self-discriminating peptide substrates for the major histocompatibility class I (MHC-I) pathway and for enhancing immune-based therapies against infected or transformed cells.
ISSN:1664-3224